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Randomised controlled trials are 
considered to be the best method to 
assess comparative clinical eicacy 
and efectiveness, and can be a key 
source of data for estimating cost 
efectiveness. Central to the design of a 
randomised controlled trial is an a 
priori sample size calculation, which 
ensures that the study has a high 
probability of achieving its prespeciied 
main objective. Beyond pure statistical 
or scientiic concerns, it is ethically 
imperative that an appropriate number 
of study participants be recruited, to 
avoid imposing the burdens of a 
clinical trial on more patients than 
necessary. The scientiic concern is 
satisied and the ethical imperative is 
further addressed by the speciication 
of a target diference between 
treatments that is considered realistic 
or important by one or more key 
stakeholder groups. The sample size 
calculation ensures that the trial will 
have the required statistical power to 
identify whether a diference of a 
particular magnitude exists. In this 
article, the key messages from the 
DELTA2 guidance on determining the 
target diference and sample size 
calculation for a randomised controlled 
trial are presented. Recommendations 
for the subsequent reporting of the 
sample size calculation are also 
provided.
Properly conducted, randomised controlled trials 
are considered to be the best method for assessing 
the comparative clinical eicacy and efectiveness of 
healthcare interventions, as well as providing a key 
source of data for estimating cost efectiveness.1 These 
trials are routinely used to evaluate a wide range of 
treatments and have been successfully used in various 
health and social care settings. Central to the design of 
a randomised controlled trial is an a priori sample size 
calculation, which ensures that the study has a high 
probability of achieving its prespeciied objective.
The diference between groups used to calculate a 
sample size for the trial (known as the target diference) 
is the magnitude of diference in the outcome of interest 
that the randomised controlled trial is designed to 
reliably detect. Reassurance in this regard is typically 
conirmed by having a sample size that has a suiciently 
high level of statistical power (typically 80% or 90%) 
for detecting a diference as big as the target diference, 
while setting the statistical signiicance at the level 
planned for the statistical analysis (usually at the two 
sided 5% level). A comprehensive methodological 
review conducted by the original DELTA (Diference 
ELicitation in TriAls) group2 3 highlighted the available 
methods and limitations in current practice. It showed 
that despite the many diferent approaches available, 
some are used only rarely in practice.4 The initial DELTA 
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guidance did not fully meet the needs of funders and 
researchers. The DELTA2 project, commissioned by the 
United Kingdom’s Medical Research Council/National 
Institute for Health Research Methodology Research 
Programme and described here, aimed to produce 
updated guidance for researchers and funders on 
specifying and reporting the target diference (the efect 
size) in the sample size calculation of a randomised 
controlled trial. In this article, we summarise the 
process of developing the new guidance, as well 
as the relevant considerations, key messages, and 
recommendations for researchers determining and 
reporting sample size calculations for randomised 
controlled trials (box 1 and table 1). 
Development of the DELta2 guidance
The DELTA2 guidance is the culmination of a ive stage 
process to meet the stated project objectives (ig  1), 
which included two literature reviews of existing 
funder guidance and recent methodological literature, 
a Delphi process to engage with a wider group of 
stakeholders, a two day workshop, and inalisation of 
the core guidance.
The literature review was conducted between April 
and December 2016 (searching up to April 2016). 
The Delphi study had two rounds: one held in 2016 
before a two day workshop in Oxford (September 
2016), and another between August and November 
2017. The general structure of the guidance was 
devised at the workshop. It was substantially revised 
on the basis of feedback from stakeholders received 
through the Delphi study. In addition, stakeholder 
engagement events were held at various meetings 
throughout the development of the guidance: the 
Society for Clinical Trials meeting and Statisticians in 
the Pharmaceutical Industry conferences both held 
in May 2017, a Joint Statistical Meeting in August 
2017, and a Royal Statistical Society Reading local 
group meeting in September 2017. These interactive 
sessions provided feedback on the scope (in 2016) 
and then draft guidance (in 2017). The core guidance 
was provisionally inalised in October 2017 and 
reviewed by the funders’ representatives for comment 
(Methodology Research Programme advisory group). 
The guidance was further revised and inalised 
in February 2018. The full guidance document 
incorporating case studies and relevant appendices 
is available here.5 Further details on the indings of 
the Delphi study and the wider engagement with 
stakeholders are reported elsewhere.6 The guidance 
and key messages are summarised in the remainder of 
this paper.
the target diference and sample size calculations in 
randomised controlled trials
The role of the sample size calculation is to determine 
how many patients are required for the planned 
analysis of the primary outcome to be informative. It is 
typically achieved by specifying a target diference for 
the key (primary) outcome that can be reliably detected 
and the required sample size calculated. In this 
summary paper, we restrict considerations to the most 
Box 1: DELTA2 recommendations for researchers undertaking a sample size calculation and choosing the target difference 
ŶũBegin by searching for relevant literature to inform the speciication of the target diference. Relevant literature can:
°ũrelate to a candidate primary outcome or the comparison of interest, and;
°ũ inform what is an important or realistic diference for that outcome, comparison, and population.ŶũCandidate primary outcomes should be considered in turn, and the corresponding sample size explored. Where multiple candidate out-
comes are considered, the choice of the primary outcome and target diference should be based on consideration of the views of relevant 
stakeholder groups (eg, patients), as well as the practicality of undertaking such a study with the required sample size. The choice should 
not be based solely on which outcome yields the minimum sample size. Ideally, the inal sample size will be suicient for all key outcomes, 
although this is not always practical.
ŶũThe importance of observing a particular magnitude of a diference in an outcome, with the exception of mortality and other serious 
adverse events, cannot be presumed to be self evident. Therefore, the target diference for all other outcomes needs additional justiication 
to infer importance to a stakeholder group.
ŶũThe target diference for a deinitive trial (eg, phase III) should be one considered to be important to at least one key stakeholder group.
ŶũThe target diference does not necessarily have to be the minimum value that would be considered important if a larger diference is con-
sidered a realistic possibility or would be necessary to alter practice.
ŶũWhere additional research is needed to inform what would be an important diference, the anchor and opinion seeking methods are to be 
favoured. The distribution method should not be used. Specifying the target diference based solely on a standardised efect size approach 
should be considered a last resort, although it may be helpful as a secondary approach.
ŶũWhere additional research is needed to inform what would be a realistic diference, the opinion seeking and the review of the evidence 
base methods are recommended. Pilot trials are typically too small to inform what would be a realistic diference and primarily address 
other aspects of trial design and conduct.
ŶũUse existing studies to inform the value of key nuisance parameters that are part of the sample size calculation. For example, a pilot trial 
can be used to inform the choice of the standard deviation value for a continuous outcome and the control group proportion for a binary 
outcome, along with other relevant inputs such as the amount of missing outcome data.
ŶũSensitivity analyses, which consider the efect of uncertainty around key inputs (eg, the target diference and the control group proportion 
for a binary outcome) used in the sample size calculation, should be carried out.
ŶũSpeciication of the sample size calculation, including the target diference, should be reported according to the guidance for reporting 
items (see table 1) when preparing key trial documents (grant applications, protocols, and result manuscripts).
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common trial design looking at a superiority question 
(one which assumes no diference between treatments 
and looks for a diference), although the full guidance 
considers equivalence and non-inferiority designs that 
invert the hypothesis and how the use of the target 
diference difers for such designs.5
The precise research question that the trial is 
primarily set up to answer will determine what needs 
to be estimated in the planned primary analysis, which 
is known formally as the “estimand.” A key part of 
characterising the research question is choosing the 
primary outcome, which needs careful consideration. 
The target diference should be a diference that 
is appropriate for that estimand.7-10 Typically (for 
superiority trials), an intention to treat or treatment 
policy estimand—that is, according to the randomised 
groups irrespective of subsequent compliance with the 
treatment allocation—is used. Other analyses that deal 
with diferent estimands8 9 11 of interest (eg, those based 
on the efect on receipt of treatment and the absence 
of non-compliance) could also inform the choice of 
sample size. Diferent stakeholders can have somewhat 
difering perspectives on the appropriate target 
diference.12 However, a key principle is that the target 
diference should be viewed as important by at least 
one (and preferably more) key stakeholder groups—
that is, patients, health professionals, regulatory 
agencies, and healthcare funders. In practice, the 
target diference is not always formally considered and 
in many cases appears, at least from trial reports, to 
be determined on convenience, the research budget, 
or some other informal basis.13 The target diference 
can be expressed as an absolute diference (eg, mean 
diference or diference in proportions) or a relative 
diference (eg, hazard or risk ratio), and is also often 
referred to, rather imprecisely, as the trial “efect size.”
Statistical calculation of the sample size is far from 
an exact science.14 Firstly, investigators typically make 
assumptions that are a simpliication of the anticipated 
analysis. For example, the impact of adjusting for 
baseline factors is diicult to quantify upfront, and 
even though the analysis is intended to be an adjusted 
one (such as when randomisation has been stratiied 
or minimised),15 the sample size calculation is often 
conducted on the basis of an unadjusted analysis. 
Secondly, the calculated sample size can be sensitive 
to the assumptions made in the calculations such that 
Table 1 | DELTA2 recommended reporting items for the sample size calculation of a randomised controlled trial with a superiority question
Recommended reporting items
Page and line numbers 
where item is reported
Core items
(1) Primary outcome (and any other outcome on which the calculation is based)
If a primary outcome is not used as the basis for the sample size calculation, state why
(2) Statistical signiicance level and power
(3) Express the target diference according to outcome type
(a)  Binary—state the target diference as an absolute or relative efect (or both), along with the intervention and control group proportions. If both 
an absolute and a relative diference are provided, clarify if either takes primacy in terms of the sample size calculation
(b)  Continuous—state the target mean diference on the natural scale, common standard deviation, and standardised efect size (mean diference 
divided by the standard deviation)
(c)  Time-to-event—state the target diference as an absolute or relative diference (or both); provide the control group event proportion, planned 
length of follow-up, intervention and control group survival distributions, and accrual time (if assumptions regarding them are made). If both an 
absolute and relative diference are provided for a particular time point, clarify if either takes primacy in terms of the sample size calculation
(4) Allocation ratio
If an unequal ratio is used, the reason for this should be stated
(5)  Sample size based on the assumptions as per above
(a)  Reference the formula/sample size calculation approach, if standard binary, continuous, or survival outcome formulas are not used. For a time-
to-event outcome, the number of events required should be stated
(b)  If any adjustments (eg, allowance for loss to follow-up, multiple testing) that alter the required sample size are incorporated, they should also 
be speciied, referenced, and justiied along with the inal sample size
(c)  For alternative designs, additional input should be stated and justiied. For example, for a cluster randomised controlled trial (or an individually 
randomised controlled trial with clustering), state the average cluster size and intracluster correlation coeicient(s). Variability in cluster size 
should be considered and, if necessary, the coeicient of variation should be incorporated into the sample size calculation. Justiication for the 
values chosen should be given
(d)  Provide details of any assessment of the sensitivity of the sample size to the inputs used
Additional items for grant application and trial protocol
(6) Underlying basis used for specifying the target diference (an important or realistic diference)
(7) Explain the choice of target diference—specify and reference any formal method used or relevant previous research
Additional item for trial results paper
(8) Reference the trial protocol
 This set of reporting items has been developed with the conventional statistical (Neyman-Pearson) approach to a sample size calculation in mind. Some of the reporting items would difer if 
another approach were to be used. This table can be downloaded as a separate document in the web appendix; page numbers can be added electronically to the PDF document.
Stage 1-2
Literature reviews
Stage 3
Delphi
Stage 4
Two day workshop
Stage 5
Finalise core guidance
Fig 1 | DELTA2 project components of work
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a small change in one of the assumptions can lead 
to substantial change in the calculated sample size. 
Often a simple formula can be used to calculate the 
required sample size. The formula varies according 
to the type of outcome, how the target diference 
is expressed (eg, a risk ratio versus a diference in 
proportions), and somewhat implicitly, the design of 
the trial and the planned analysis. Typically, a sample 
size formula can be used to calculate the required 
number of observations in the analysis set, which 
varies depending on the outcome and the intended 
analysis. In some situations, ensuring the sample size 
is suicient for more than one planned analysis may be 
appropriate.
When deciding on the sample size for a randomised 
controlled trial, it is necessary for researchers to 
balance the risk of incorrectly concluding that there 
is a diference when no actual diference between the 
treatments exists, with the risk of failing to identify a 
meaningful treatment diference when the treatments 
do difer. Under the conventional approach, referred 
to as the statistical hypothesis testing framework,16 
the probabilities of these two errors are controlled 
by setting the signiicance level (type I error) and 
statistical power (1 minus type II error) at appropriate 
levels (typical values are two sided 5% signiicance 
and 80% or 90% power, respectively). Once these 
two inputs have been set, the sample size can be 
determined given the magnitude of the between 
group diference in the outcome it is desired to detect 
(the target diference). The calculation (relecting 
the intended analysis) is conventionally done on the 
basis of testing for a diference of any magnitude. As 
a consequence, it is essential when interpreting the 
analysis of a trial to consider the uncertainty in the 
estimate, which is relected in the conidence interval. 
A key question of interest is what magnitude of 
diference can be ruled out. The expected (predicted) 
width of the conidence interval can be determined for 
a given target diference and sample size calculation, 
which is another helpful aid in making an informed 
choice about this part of a trial’s design.17 Other 
statistical and economic approaches to calculating 
the sample size have been proposed, such as precision 
and bayesian based approaches16  18-20 and the value 
of information analysis,21 although they are not at 
present commonly applied.22
The required sample size is very sensitive to the 
target diference. Under the conventional approach, 
halving the target diference quadruples the sample 
size for a two arm, 1:1, parallel group superiority trial 
with a continuous outcome.23 Appropriate sample size 
formulas vary depending on the proposed trial design 
and statistical analysis, although the overall approach 
is consistent. In more complex scenarios, simulations 
can be used but the same general principles hold. It 
is prudent to undertake sensitivity calculations to 
assess the potential efect of misspeciication of key 
assumptions (such as the control response rate for 
a binary outcome or the anticipated variance of a 
continuous outcome).
The sample size calculation and the target 
diference, if well speciied, help provide reassurance 
that the trial is likely to detect a diference at least as 
large as the target diference in terms of comparing the 
primary outcome between treatments. Failure to clarify 
suiciently what is important and realistic at the design 
stage can lead to subsequent sample size revisions, 
or an unnecessarily inconclusive trial due to lack of 
statistical precision or ambiguous interpretation of 
the indings.24 25 When specifying the target diference 
with a deinitive trial in mind, the following guidance 
should be considered.
Specifying the target diference for a randomised 
controlled trial
Diferent statistical approaches can be taken to specify 
the target diference and calculate the sample size 
but the general principles are the same. To aid those 
researchers new to the topic and to encourage better 
practice and reporting regarding the speciication of 
the target diference for a randomised controlled trial, 
a series of recommendations is provided in box 1 and 
table 1. Seven broad types of methods can be used to 
justify the choice of a particular value as the target 
diference, which are summarised in box 2.
Broadly speaking, two diferent approaches can be 
taken to specify the target diference for a randomised 
controlled trial. A diference that is considered to be:
ŶũImportant to one or more stakeholder groups
ŶũRealistic (plausible), based on either existing evi-
dence, or expert opinion.
A large literature exists on deining and justifying 
a (clinically) important diference, particularly for 
quality of life outcomes.27-29 In a similar manner, 
discussions of the relevance of estimates from existing 
studies are also common; there are several potential 
pitfalls to their use, which needs careful consideration 
of how they should inform the choice of the target 
diference.2 It has been argued that a target diference 
should always be both important and realistic,30 which 
would seem particularly apt when designing a deinitive 
(phase 3) superiority randomised controlled trial. In a 
sample size calculation for a randomised controlled 
trial, the target diference between the treatment 
groups strictly relates to a group level diference for the 
anticipated study population. However, the diference 
in an outcome that is important to an individual might 
difer from the corresponding value at the population 
level. More extensive consideration of the variations in 
approach is provided elsewhere.2 3
reporting the sample size calculation
The approach taken to determine the sample size and 
the assumptions made should be clearly speciied. This 
information should include all the inputs and formula 
or simulation results, so that it is clear what the 
sample size was based on. This information is critical 
for reporting transparency, allows the sample size 
calculation to be replicated, and clariies the primary 
(statistical) aim of the study. Under the conventional 
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approach with a standard trial design (1:1 allocation, 
two arm, parallel group, superiority design) and 
unadjusted statistical analysis, the core items that 
need to be stated are the primary outcome, the target 
diference appropriately speciied according to the 
outcome type, the associated nuisance parameter (that 
is, a parameter that, together with the target diference, 
uniquely speciies the diference on the original 
outcome scale—eg, the event rate in the control group 
for a binary primary outcome), and the statistical 
signiicance and power. More complicated designs can 
have additional inputs that should be considered, such 
as the intracluster correlation for a cluster randomised 
design.
A set of core items should be reported in all key 
trial documents (grant applications, protocols, and 
main results papers) to ensure reproducibility and 
plausibility of the sample size calculation. The full list 
of recommended core items are given in table 1, which 
is an update of the previously proposed list.31 When the 
sample size calculation deviates from the conventional 
approach, whether by research question or statistical 
framework, the core reporting set can be modiied 
to provide suicient detail to ensure that the sample 
size calculation is reproducible and the rationale for 
choosing the target diference is transparent. However, 
the key principles remain the same. If the sample size 
is determined on the basis of a series of simulations, 
this method should be described in suicient detail 
to provide an equivalent level of transparency and 
assessment. Additional items to give more explanation 
of the rationale should be provided if space allows (eg, 
in grant applications and trial protocols). Trial result 
publications can then reference these documents 
if suicient space is not available to provide a full 
description.
Box 2: Methods that can help inform the choice of the target difference
Methods that inform what is an important difference
ŶũAnchor: The outcome of interest can be anchored by using either a patient’s or health professional’s judgment 
to deine what an important diference is. This approach can be achieved by comparing a patient’s health 
before and after treatment and then linking this change to participants who showed improvement or deteri-
oration using a more familiar outcome (for which either patients or health professionals more readily agree 
on what amount of change constitutes an important diference). Contrasts between patients (eg, individuals 
with varying severity of a disease) can also be used to determine a meaningful diference.
ŶũDistribution: Approaches that determine a value based on distributional variation. A common approach is to 
use a value that is larger than the inherent imprecision in the measurement and therefore likely to represent 
a minimal level needed for a noticeable diference.
ŶũHealth economic: Approaches that use the principles of economic evaluation. These approaches compare 
cost with health outcomes, and deine a threshold value for the cost of a unit of health efect that a decision 
maker is willing to pay, to estimate the overall incremental net beneit of one treatment versus the compar-
ator. A study can be powered to exclude a zero incremental net beneit at a desired statistical signiicance 
and power. A radically diferent approach is a (bayesian) decision-theoretic value of information analysis 
that compares the added value with the added cost of the marginal observation, thus avoiding the need to 
specify a target diference.
ŶũStandardised efect size: The magnitude of the efect on a standardised scale deines the value of the dif-
ference. For a continuous outcome, the standardised diference can be used (most commonly expressed as 
Cohen’s d efect size, the mean diference divided by the standard deviation). Cohen’s cutof sizes of 0.2, 0.5, 
and 0.8 are often used for small, medium, and large efects, respectively. Thus, a medium efect corresponds 
simply to a diference in the outcome of 0.5 standard deviations. When measuring a binary or survival (time-
to-event) outcome, alternative metrics (eg, an odds, risk, or hazard ratio) can be used in a similar manner, 
although no widely recognised cutof points exist. Cohen’s cutof points approximate odds ratios of 1.44, 2.48, 
and 4.27, respectively.26 Corresponding risk ratio values vary according to the control group event proportion.
Methods that inform what is a realistic difference
ŶũPilot study: A pilot (or preliminary) study may be carried out if there is little evidence, or even experience, 
to guide expectations and determine an appropriate target diference for the trial. Similarly, a phase 2 study 
could be used to inform a phase 3 study, although this approach would need to take account of methodolog-
ical diferences (eg, inclusion criteria and outcomes) that should be relected in speciication of the target 
diference.
Methods that inform what is an important or a realistic difference
ŶũOpinion seeking: The target diference can be based on opinions elicited from health professionals, patients, 
or others. Possible approaches include forming a panel of experts, surveying the membership of a profes-
sional or patient body, or interviewing individuals. This elicitation process can be explicitly framed within 
a trial context.
ŶũReview of evidence base: The target diference can be derived from current evidence on the research question. 
Ideally, this evidence would be from a systematic review or meta-analysis of randomised controlled trials. In 
the absence of randomised evidence, evidence from observational studies could be used in a similar manner.
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Discussion
Researchers are faced with a number of diicult 
decisions when designing a randomised controlled 
trial, the most important of which are the choice of 
trial design, primary outcome, and sample size. The 
sample size is largely driven by the choice of the target 
diference, although other aspects of sample size 
determination also contribute.
The DELTA2 guidance provides help on specifying 
a target diference and undertaking and reporting the 
sample size calculation for a randomised controlled 
trial. The guidance was developed in response to a 
growing recognition from funders, researchers, and 
other key stakeholders (such as patients and the 
respective clinical communities) of a real need for 
practical and accessible advice to inform a diicult 
decision. The new guidance document therefore 
aims to bridge the gap between the existing (limited) 
guidance and this growing need.
The key message for researchers is the need to be 
more explicit about the rationale and justiication 
of the target diference when undertaking and 
reporting a sample size calculation. Increasing focus 
is being placed on the target diference in the clinical 
interpretation of the trial result, whether statistically 
signiicant or not. Therefore, the speciication and 
reporting of the target diference, and other aspects of 
the sample size calculation, needs to be improved.
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